Dac Nadia 4

What Happened

Nadia Dac, Chief Commercial Officer of Kyverna Therapeutics (KYTX), was granted an equity award for 300,000 shares on May 4, 2026. The reported acquisition is coded as an award/other acquisition (derivative) at $0.00 per share (no cash paid at grant). This is a grant rather than a purchase or sale.

Key Details

• Transaction date: May 4, 2026; Form 4 filed May 6, 2026.
• Transaction type/code: Grant / Award (code A); derivative security reported at $0.00 per share for 300,000 shares.
• Shares owned after transaction: Not disclosed in the filing.
• Vesting (per footnote): 25% vests on May 4, 2027; thereafter 1/48th of the total shares vest each month, subject to continued service (i.e., time-based vesting until fully vested).
• Filing timeliness: Form filed two days after the grant (appears timely under Form 4 rules).

Context

This is a time-based equity award (e.g., restricted stock units or similar derivative award) that vests over a multi-year schedule; it does not represent an immediate cash purchase or sale of shares. Such grants are a common part of executive compensation and do not, by themselves, indicate the insider is buying or selling stock.